ARCHIVES

Expanded Tissue Resources, Equipment Funds Planned.

This article is from The Cancer Letter archive.

Vol. 26 No. 45 | December 8, 2000

Download PDF Visit The Full Archive

Related Articles

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

April 27, 2012

Bristol-Myers, IVAX submit Competing Application for Paclitaxel Use In KS

April 18, 1997

In Brief: ACS Board Names McGinnis Prsident; Fuller Re-Elected chairman; Lenhard Is Vice President

November 25, 1994

Cancer Pain Treatment Guide Published By NCCN, ACS

April 27, 2001

Adjuvant XELOX More Effective Than 5-FU/LV For Stage III Colon Cancer

January 29, 2010

In Brief: Three Centers Win Comprehensive Designation; Hiatt Named Deputy Director, NCI Cancer Control

October 31, 1997